China Beefs Up Quality Control System With New GMP Regulations: Shanghai FDA Leaders At PharmAsia Summit
This article was originally published in PharmAsia News
SAN FRANCISCO - China is releasing a new edition of its good manufacturing practice regulations and introducing other measures to strength its pharmaceutical quality control system. China's State FDA is placing more focus on reviewing drugs for approval while provincial-level regulators have stepped-up responsibility for inspecting drug makers and monitoring drugs on the market, said Shanghai FDA officers who spoke at the PharmAsia Summit this week in San Francisco
You may also be interested in...
Insider Analysis From Asia Pacific Bio Intelligence LLC On China State FDA’s Medical Device Regulations
For China’s State FDA, 2011 was a banner year, with regulations released on good manufacturing practices for both drugs and devices. Multinational companies should take notice and be sure their operations are in compliance.
SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China
China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys
SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems